european crystal network workshop

    Program

    Thursday March 14, 2019

     

  • AM session

  • 08:30 - 09:00
  • Frédéric Lioté (Paris, France), Fernando Perez-Ruiz (Biskay, Spain), Alex So (Lausanne, Switzerland)

    Welcome and introduction

  • 09:00 - 09:30
  • Björne Busse (Hambourg, Germany)

    Microanalytical characterization of calcification in human tissue

  • 09:30 - 10:00
  • Claudia Goettsch (Germany)

    Microcalcification - a cardiovascular risk factor

  • 10:00 - 10:30
  • Magnus Bäck (Stockholm, Sweden)

    RISK FACTORS AND MECHANISMS IN CALCIFIC AORTIC STENOSIS

  • 10:30 - 11:00
  • Coffee break

  • 11:00 - 11:30
  • Sonia Nasi (Lausanne, Switzerland)

    H2S and calcification: updates

  • 11:30 - 12:00
  • Jessica Bertrand (Magdeburg, Germany)

    BCP crystals regulating ECM sulfation and downstream signaling cascades

  • 12:00 - 12:45
  • 3 Oral communications including 2019 ECN Prize

  • 12:45 - 14:00
  • Lunch and networking – Poster tour

  • PM session

  • 14:00 - 14:30
  • Nathalie Busso / Driss Ehirchiou (Lausanne, Switzerland)

    New biological roles for xanthine oxidoreductase

  • 14:30 - 15:00
  • Fabio Becce (Lausanne, Switzerland), Tristan Pascart (Lille, France)

    NEW INSIGHTS INTO IMAGING OF CALCIUM CRYSTAL DEPOSITION DISEASES

  • 15:00 - 15:30
  • Hang-Korng Ea (Paris, France)

    Gitelman disease and calcifications

  • 15:30 - 16:00
  • Leo Joosten (Nijmegen, Holland)

    Epigenetics modification by urate

  • 16:00 - 16:30
  • Coffee break

  • 16:30 - 17:00
  • Robert Terkeltaub (San Diego, USA)

    Variability of gouty inflammation

  • 17:00 - 17:45
  • 3 Oral communications

    Friday March 15, 2019

     

  • AM session

  • 08:30 - 09:00
  • Anna Kottgen (Freiburg, Germany)

    Updates in genetics of serum urate

  • 09:00 - 09:30
  • Tony Merriman (Dunedin, NZ)

    GWAS update and gout

  • 09:30 - 10:00
  • Richard Reynolds (Birmingham, USA)

    Profiling genomic regions for joint effects on serum urate and gout

  • 
  • 10:00 - 10:30
  • David Mount (Boston, USA)

    Insulin and IGF-1: genetic and physiological influences on human uric acid homeostasis

  • 10:30 - 11:00
  • Coffee break

  • 10:45 - 11:30
  • Hyon Choi (Boston, USA)

    Dissecting and Tackling the Modern Gout Epidemic – Advances in the Epidemiology of Gout

  • 
  • 11:30 - 12:15
  • Mihai G. Netea (Nijmegen, Holland)

    Keynote ECN 2019: Trained immunity and cardiovascular diseases

  • 12.15 - 12.30
  • Michael Doherty (Nottingham, United Kingdom)

    Prophylaxis during initial ULT, and combination ULT – where do we stand?

  • 12:30 - 13:00
  • 2 Oral communications

  • 13:00 - 14:00
  • Lunch time and poster viewing

  • PM session

  • 14:00 - 14:30
  • Nicola Dalbeth (Auckland, NZ)

    Patient related outcomes: Illness perceptions and gout

  • 14:30 - 15:00
  • Abhishek Abhishek (Nottingham, UK)

    Patients’ related outcomes: improving adherence

  • 15:00 - 15:30
  • Mats Dehlin (Sweden)

    Burden of disease: hospitalization and work disability

  • 15:30 - 16:00
  • Pascal Richette (Paris, France)

    clusters of comorbidities and gout

  • 16:00 - 16:30
  • Coffee break

  • 16:30 - 17:30
  • The big controversy 2019

  • Eliseo Pascual (Alicante, Spain)

    Gout is a histopathological entity (crystals in tissues is gout) (30min including Q&A)

  • 
  • George Nuki (Edinburg, Scotland)

    GOUT IS A CLINICAL ENTITY (30 min including Q&A)

  •  

    Symposium

    Crowne Plaza République

    > Limited number of participants

     

    Difficult-to-treat gout: comorbidities to consider

    Moderator: Frédéric Lioté (Paris, France)

  • 19:30
  • Welcome

  • 20:00 - 21:00
  • Symposium

    Moderator: Frédéric Lioté (Paris, France)

  •  
  • Austin Stack (Limerick, Ireland)

    Gout: set the scene with renal diseases - established chronic kidney disease (stages 3-5)

  •  
  • Frank Paganelli (Marseille, France)

    Gout: set the scene with CV diseases - established heart disease (cardiac failure, CAD)

  •  
  • Fernando Perez-Ruiz (Bilbao, Spain)

    Management of gout patients with comorbidities